Jon Ogg

Jon Ogg is co-founder and editor for 24/7 Wall St.

Jon has worked as a news analyst for nearly 10 years and also has experience as a broker, portfolio manager and investment adviser. He has been sourced for articles in CBS MarketWatch, E*Trade, TradeTheNews, FlyOnTheWall, Pristine, Evolution Trading, Knova Trading, Hammerstone, CNet.com, Seeking Alpha, Google Finance and other sites.

Prior to 24/7 Wall St., he formed News Contrast and was the founder of a service for active traders called TradeTheNews (which he sold in 2003) and built up a news desk that was merged into E*Trade. He also worked in Copenhagen, Denmark as a portfolio manager for European clients trading U.S. equities and ran the event-driven trading team there.

He has been a financial adviser and has advised start-up and emerging-stage companies, and started his career as a licensed broker selling fixed income to some of the largest investment managers in the United States. He received a B.B.A. in Finance from the University of Houston (1992).

Jon does not hold any positions in any stocks he writes about.

Recent Articles

2 Ways to Profit From RIMM’s Struggles

By Jon Ogg

BlackBerry-maker Research In Motion Limited (NASDAQ: RIMM) is losing market share to iPhones and Droids. Here are two ways to play the stock's slide.

China Yuan Investing – Chinese ETFs CYB and FXI

By Jon Ogg

China is revaluing its currency, the yuan, in a way. China pledged over the weekend to allow greater flexibility in exchange rates for the currency. Forex investors cheered this This is the second move to de-peg the yuan or renminbi against the U.S. Dollar but it is not a free-float of their exchange rates. The good news is that there is an ETF for this via the WisdomTree Dreyfus Chinese Yuan (NYSE: CYB).

High Dividend Yield Stocks – Where’s the Biotech Payday? (AMGN, GENZ, BBH, PFE, MRK)

By Jon Ogg

Amgen Inc. (NASDAQ: AMGN) and Genzyme Corporation (NASDAQ: GENZ) are two dead money biotech giants which are trying to turn their ships around. The reason for each being dead as a stock is a night and day difference. But both have a quest to boost long-term value, and so far both have resisted the call to begin making high yield dividend payments.

BP Calls Could Deliver Some Slick Profits

By Jon Ogg

BP plc (NYSE: BP) will be in trouble for quite some time, but with the stock near its 52-week low, these longer-term call options could pay off.

Sallie Mae Looks Like a Smart Trade

By Jon Ogg

Buying call options on student loan company SLM Corporation (NYSE: SLM) could have you feeling pretty smart this summer.

Load More